Mar 27, 2013
Generic Cancer Part 1: What is Generic Cancer, Does Generic Cancer Kill?
cancer'? Is there such a thing as generic cancer? How common is it? What causes
tracychess
10 minSearch Research
Search across 105,000+ research abstracts, articles, substances, health topics, keywords, and actions.
Looking for the health topic Cancer? View in Explore →
Found 18 results for "Cancer"
Articles (6)
View all
Feb 27, 2013
Cancer & Sugar - Strategy for Selective Starvation of Cancer
cancer is "weak" or only "nominally significant." They believe that research "linking foodstuffs to cancer
drsircus
14 min
May 26, 2014
Thyroid Cancer Epidemic Caused by Misinformation, Not Cancer
cancer diagnoses are FALSE? And yet, the vast majority go ahead and get 'treated' anyway
Sayer Ji
10 min
Mar 29, 2013
Generic Cancer: Part 2: Is “generic cancer” a disease of the cells, or a disease of the tissues?
cancer. Cancers are classified by tissues, but treatments attack malignant cells and ignore - or worse
tracychess
11 min
Feb 02, 2023
'Oops... It Wasn't Cancer After All,' Admits The National Cancer Institute/JAMA
cancer diagnoses and treatments, and millions harmed, the National Cancer Institute and high gravitas journals
Sayer Ji
7 minAbstracts (6)
View allTanshinone IIA inhibits malignant progression in a spontaneous breast cancer mouse model by attenuating tissue factor-mediated angiogenesis.
<p>INTRODUCTION: As a classic botanical drug, Salvia miltiorrhiza Bunge has long been used to promote blood circulation and remove blood stasis. Tanshinone IIA (Tan IIA), a major bioactive diterpenoid derived from its roots, shows promising therapeutic potential, but its chemopreventive actions against early tumor progression have not been fully clarified. This study aims to comprehensively examine the chemopreventive potential of Tan IIA, specifically focusing on the poorly studied adenoma-to-early-carcinoma transition in breast cancer, and elucidate its underlying anti-angiogenic mechanisms. METHODS: We adopted the mouse mammary tumor virus-polyoma virus middle T antigen (MMTV-PyMT) transgenic mouse model, which recapitulates the natural progression of spontaneous breast tumorigenesis. A combination of pharmacokinetic analysis, network pharmacology, in vivo histopathology, immunofluorescence (IF) staining, multiple angiogenesis assays, and molecular experiments, including qPCR, Western blot, and cellular thermal shift assay (CETSA), was applied for comprehensive evaluation. RESULTS: Our results demonstrated that Tan IIA markedly delayed the malignant transformation of benign mammary tumors. Pharmacokinetic characterization confirmed the favorable in vivo bioavailability of Tan IIA and its metabolites. Mechanistically, Tan IIA significantly downregulated tissue factor (TF), a critical driver of tumor angiogenesis. This reduction in TF expression was accompanied by decreased levels of vascular endothelial growth factor A (VEGFA) and other pro-angiogenic factors. DISCUSSION: Our work reveals that Tan IIA exerts prominent chemopreventive effects against breast precancerous lesions, mainly by suppressing TF-mediated angiogenesis, indicating its great promise as a candidate agent for early breast cancer intervention.</p>
Wang Y, Yan X, Wang Z, Sun Y, Zhu Z, Mao T, Wang Q, Fan X, Lu X, Xu J, Li X, Lu Y, Wu Y, Frontiers in pharmacology
Transgenic Animal Study
Mechanism by which Icariin suppresses pulmonary metastasis in triple-negative breast cancer.
Triple-negative breast cancer (TNBC), a distinct subtype of breast cancer, is characterized by the concurrent absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in tumor tissues. This molecular phenotype renders current endocrine and targeted therapies ineffective, underscoring the urgent need to explore novel therapeutic targets. This study focused on icariin (ICA), a bioactive flavonoid derived from the traditional Chinese herb Epimedium, and systematically elucidated its mechanism in suppressing TNBC progression on the basis of its unique antitumor pharmacological properties. In vitro cell models and an in vivo pulmonary metastasis mouse model revealed that ICA significantly inhibited the malignant biological behaviors of TNBC cells (proliferation, invasion, and metastasis). RNA sequencing revealed significant alterations in the expression of key molecules of the JAK-STAT signaling pathway. Mechanistic investigations demonstrated that ICA suppressed the phosphorylation and activation of the JAK2/STAT3 signaling axis by downregulating spindle apparatus coiled-coil protein 1 (SPDL1). These experimental data confirmed that modulation of the SPDL1/JAK2/STAT3 signaling pathway constitutes the molecular basis of the anti-TNBC effects of ICA. This study elucidated the anti-TNBC mechanism of ICA at the signal transduction level, providing an innovative theoretical foundation for the development of natural product-based targeted therapies.
Zengyou Xiao, Zean Yang, Xiaotong Li, Xin Chen, Jiaxian Li, Yujie He, Wei Li, Jie Wang, Cancer Cell Int
Animal Study
Qualitative study on body image disturbance in young and middle-aged women with breast cancer in China.
OBJECTIVES: To explore how young and middle-aged Chinese women with breast cancer perceive and emotionally respond to changes in their physical appearance and function during treatment and social interactions. DESIGN: A descriptive phenomenological qualitative study using Colaizzi's seven-step analysis method. SETTING: Breast surgery departments of two tertiary hospitals in North and Central China. PARTICIPANTS: This study included a purposive sample of 18 young and middle-aged women (18-59 years old) with pathologically confirmed breast cancer who had received a mastectomy and obtained a score ≥10 on the Body Image Scale. DATA COLLECTION AND ANALYSIS: In-depth, semi-structured face-to-face interviews were conducted from January to October 2024 to collect data. The data were analysed using Colaizzi's phenomenological analysis method to identify and interpret the main themes representing participants' lived experiences. RESULTS: Four main themes and 11 sub-themes were identified. Theme 1, 'Perceived social group pressure', included family burdens, peer influence and public scrutiny. Theme 2, 'Emotional reactions to social pressure', covered strong desire to survive, ambivalence towards visits and existential confusion. Theme 3, 'Perception of physical changes', involved feelings of physical weakness, hair loss and body shame, weight and self-image bias. In Theme 4, 'Coping and Meaning Reconstruction', there were social withdrawal and the experience of positive psychological growth after encountering adversity. CONCLUSIONS: The research describes the psychological and social pressures breast cancer patients and survivors experience during treatment and gives recommendations to garner understanding and support for this patient group concerning body image disturbance. TRIAL REGISTRATION: Not applicable.
Liu H, Wang L, Gao J, Zhang Q, Zhang X, Gao Y, Guo J, BMJ open
Perioperative chemoimmunotherapy for patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.
BACKGROUND: The addition of immune checkpoint inhibitors (ICIs) to perioperative treatment for resectable gastric or gastroesophageal junction (GEJ) cancers has shown promising results. However, current pivotal trials (KEYNOTE-585 and MATTERHORN) have reported conflicting survival outcomes. To clarify their therapeutic value, we conducted a meta-analysis evaluating the efficacy and safety of adding ICIs to this population. METHODS: PubMed, Embase, and major oncology conference abstracts were systematically searched for randomized controlled trials (RCTs) comparing ICIs plus chemotherapy versus chemotherapy alone in patients with resectable gastric or GEJ adenocarcinoma. Outcomes included pathological complete response (pCR), event-free survival (EFS), overall survival (OS), and treatment-related adverse events (TRAEs). Risk differences (RDs) and hazard ratios (HRs) were pooled using a fixed-effect model meta-analysis. RESULTS: Seven RCTs involving 2510 patients were included. Compared with chemotherapy alone, chemoimmunotherapy significantly improved pCR (17.6% vs. 6.1%; RD = 0.11, 95% CI = 0.09 to 0.14, P < .001), EFS (HR = 0.76, 95% CI = 0.66 to 0.86, P < .001), and OS (HR = 0.82, 95% CI = 0.71 to 0.94, P = .005). Subgroup analyses showed statistically significant efficacy in PD-L1 positive tumors, whereas no significant benefit was observed in PD-L1 negative patients. Grade ≥3 TRAEs were not significantly increased with chemoimmunotherapy (66.1% vs. 62.7%; RD = 0.04, 95% CI = 0.00 to 0.08, P = .08). CONCLUSIONS: The addition of ICIs to perioperative chemotherapy improves pathological and survival outcomes in resectable gastric or GEJ cancers, particularly in PD-L1 positive populations, without increasing grade ≥3 TRAEs. These findings support chemoimmunotherapy as a promising curative strategy.
Omori R, Fujiwara Y, Tokunaga K, Sato T, Mukherjee S, JNCI cancer spectrum
Targeted photodynamic therapy for pancreatic cancer: recent innovations from fundamentals to and clinical applications (2020-2025).
Photodynamic therapy (PDT) is a clinically-approved medical modality to treat different types of localised conditions such as cancer, infections or skin conditions. Pancreatic cancer (PC) is a deadly cancer displaying a dramatic overall prognosis that has barely improved in decades as the majority of PC patients are diagnosed at a locally advanced or metastatic stage and cannot benefit of surgical resection which is the only curative treatment, the overall 5-year survival rate remains extremely low. Thus, finding new therapies for non-metastatic PC to improve local control as a bridge to surgical resection and improve survival outcomes remains a huge challenge. In this context, PDT could be an interesting option. This review will focus on the use of PDT with targeted photosensitisers or nanoparticles to treat PC in recent studies (2020-2025) from to experiments and clinical applications.
Sarr S, Godard J, Valzer E, Czuba E, Acherar S, Barberi-Heyob M, Blanchard-Desce M, Boleslawski E, Brégier F, Bulin AL, Burckel H, Daouk J, da Silva A, Daniel J, Delhem N, Dewalle AS, Frochot C, Gasser G, Heitz V, Jonckheere N, Lemercier G, Mordon S, Noël G, Novell A, Ravanat JL, Roth G, Sol V, Chemical communications (Cambridge, England)
Videos (6)
View all
Video Feed
Aug 3, 2014
The Top 3 Cancer Fighting Nuts
Within hours the blood of those fed walnuts is able to suppress the growth of breast cancer cells in a petri dish. Which nut might work best, though–almonds, Brazil nuts, cashews, hazelnuts, macadamia...
1,418 views
Video Feed
Mar 20, 2013
Why Sunscreen Use Promotes Cancer
It's advertised as something that can help you prevent cancer. But Dr. Elizabeth Plourde explains how sunscreen use actually increases cancer risk. She also talks about how different kinds of sunscree...
1,399 views
Video Feed
Apr 8, 2013
Chemotherapy Doesn't Work 97% Of The Time–Dr. Glidden
Dr. Peter Glidden cites a recent study that concludes better than 97% of the time, chemotherapy does not work. Yet it's one of the main treatments in the battle against cancer. Dr. Glidden explains wh...
901 views
Video Feed
Mar 17, 2013
Breast Thermography vs. Mammography: Gaea Powell
"In January 2011, a study by the Mayo Clinic found in women with dense breast tissues 75% of cancers were missed by mammography alone. 40%-50% of women have dense breast tissue yet 95% of women are un...
712 views
Video Feed
Feb 2, 2016
Should We All Get Colonoscopies Starting at Age 50?
Why do U.S. doctors continue to recommend colonoscopies when most other countries recommend less invasive colon cancer screening methods? The post Should We All Get Colonoscopies Starting at Age 50? a...
616 views
Health Guides (2)
Cancer
There are thousands of studies on the National Library of Medicine concerning natural substances which have experimentally confirmed anti-cancer activity. Moreover, the research on unintended, adverse...
46 articles
Health Guide: Breast Cancer
This section collates research and information relevant to natural breast cancer treatment. It is designed to provide our users with the first-hand research on conventional medical interventions and p...
26 articles
